BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32864192)

  • 1. Risk factors and outcome of COVID-19 in patients with hematological malignancies.
    Piñana JL; Martino R; García-García I; Parody R; Morales MD; Benzo G; Gómez-Catalan I; Coll R; De La Fuente I; Luna A; Merchán B; Chinea A; de Miguel D; Serrano A; Pérez C; Diaz C; Lopez JL; Saez AJ; Bailen R; Zudaire T; Martínez D; Jurado M; Calbacho M; Vázquez L; Garcia-Cadenas I; Fox L; Pimentel AI; Bautista G; Nieto A; Fernandez P; Vallejo JC; Solano C; Valero M; Espigado I; Saldaña R; Sisinni L; Ribera JM; Jimenez MJ; Trabazo M; Gonzalez-Vicent M; Fernández N; Talarn C; Montoya MC; Cedillo A; Sureda A;
    Exp Hematol Oncol; 2020; 9():21. PubMed ID: 32864192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
    Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
    Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
    Goudsmit A; Cubilier E; Meert AP; Aftimos P; Stathopoulos K; Spilleboudt C; Loizidou A
    Support Care Cancer; 2021 Nov; 29(11):6271-6278. PubMed ID: 33851236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation.
    Harada K; Sekiya N; Konishi T; Nagata A; Yamada Y; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Sasaki S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
    BMC Infect Dis; 2017 Sep; 17(1):638. PubMed ID: 28938875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.
    Shah NN; McClellan W; Flowers CR; Lonial S; Khoury H; Waller EK; Langston A; Nooka AK
    Infect Control Hosp Epidemiol; 2017 Jun; 38(6):651-657. PubMed ID: 28330512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Chevallier P; Labopin M; Milpied N; Bilger K; Socié G; Yakoub-Agha I; Michallet M; Bulabois CE; Maury S; Beguin Y; Bay JO; Blaise D; Maillard N; Guillerm G; Daguindeau E; Raus N; Mohty M
    Bone Marrow Transplant; 2014 Mar; 49(3):361-5. PubMed ID: 24292522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study.
    Acar IH; Guner SI; Ak MA; Gocer M; Ozturk E; Atalay F; Sincan G; Yikilmaz AS; Ekinci O; Ince I; Gulturk E; Demir N; Dogan A; Ipek Y; Guvenc B
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022074. PubMed ID: 36425152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Severity in Covid-19 Patients in Casablanca, Morocco.
    El Aidaoui K; Haoudar A; Khalis M; Kantri A; Ziati J; El Ghanmi A; Bennis G; El Yamani K; Dini N; El Kettani C
    Cureus; 2020 Sep; 12(9):e10716. PubMed ID: 33033687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
    Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
    Shahzad M; Chaudhary SG; Zafar MU; Hassan MA; Hussain A; Ali F; Anwar I; Ahmed M; Ahmed N; Khurana S; Rauf MA; Anwar F; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Infect Dis; 2022 Apr; 24(2):e13792. PubMed ID: 35030267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
    García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C;
    Eur J Haematol; 2019 Jun; 102(6):465-471. PubMed ID: 30828868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting mortality in geriatric patients hospitalized with COVID-19.
    Bağ Soytaş R; Ünal D; Arman P; Suzan V; Emiroğlu Gedik T; Can G; Korkmazer B; Karaali R; Börekçi Ş; Kuşkucu MA; Yavuzer H; Suna Erdinçler D; Döventaş A
    Turk J Med Sci; 2021 Apr; 51(2):454-463. PubMed ID: 33315348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH).
    Diaz MA; Gonzalez-Vicent M; Gonzalez ME; Verdeguer A; Martinez A; Perez-Hurtado M; Badell I; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S; ;
    Bone Marrow Transplant; 2005 Nov; 36(9):781-5. PubMed ID: 16151427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies.
    Yun S; Vincelette ND; Abraham I; Puvvada S; Anwer F
    Acta Haematol; 2016; 136(4):244-255. PubMed ID: 27802434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.